Good and joining for evening, us. thanks
discuss quarter execution of to strong against another here be plan. to pleased We’re our
key reiterate context of As I three plan. elements call, to want for that today’s
existing clients. a First, and with new strategy attracting our value-based for clients growth integrated specialty management organic by winning approach is a driven that conviction expanding both
inherent and And our the sheet Second, including thoughtful expansion delevering. commitment operating to our in ability margin given earnings generation maturation third, drive balance management, cash leverage business. our to and
adjusted and see our of another we’ve taken of exiting plan, continued sales towards then results all next I thereafter. this momentum $XXX with think our this million target EBITDA year elements step affirm of three quarter you’ll
quarter. to the Turning
of end quarter, at came Second above adjusted the EBITDA right quarter our high in while the outlook revenue was for midpoint. the
by driven organic quarter-over-quarter year-over-year. Specifically, and substantial both growth membership strong was revenue growth
driven initial profit Our fee-based growth plus our portfolio, from high work. revenue business, from NIA of integration from acquired the our Performance incremental by and benefits year-on-year Suite flow-through services, continued was technology maturation margins
quarter the the visibility results are Given for adjusted we outlook. of our of the XXXX, our for the midpoint and EBITDA remainder raising XXXX
and as shortly. more we maintaining provide are For XXXX client the based significant on several the revenue, three timing outlook well four. outlook quarter will detail our go-lives across third of as John quarters
remainder Arizona in live anticipate we January. of guide went July, the of the Florida we year. contract live As this announced later from the in continued Suite part year, for to plan and past the growth Performance in Humana That this go
contributing the above also and Our expectations, other are or remainder at new existing high XXXX. performing confidence in of contracts to
quarter’s Looking of focus XX% revenues was of of million, first growth XX% revenue. with at on the XX% was acquisitions XX.X% second quarter numbers, approximately to over period this compared grew Total growth XX.X briefly the growth. $XXX.X representing total same points Sequentially, revenue XXXX. Evolent’s quarter XXXX. of specialty XXXX of Evolent’s year-on-year We the contributing revenue reported
grew of impact year-over-year. base the Evolent’s core over specialty XX% acquisitions, before So
by adjusted as compared EBITDA addition base well to quarter year. EBITDA million, expansion of Second in the quarter than the more and totaled acquisitions. as adjusted last was business The in year-over-year doubling NIA $XX.X growth of the the both IPG second driven
we new of and expansions. as per consisting growth, our two Now of quarter the allocation. expanding with to as year of eight partners organic of priorities milestone to six members that Evolent we announce of optimal cross-sell an market. to and important margins strong against agreements, both Performance pleased marks Florida. four heels for turn organic and Evolent’s Performance operating in new operating first Oncology Cardiology growth, exchange on target Florida three robust the agreement MA agreement let’s well in had are we years will success for two of capital Starting Suite Medicaid the core This partnerships, Starting a to with our expand as operating new new in Molina’s Suite Medicaid two first
states to including able states X.X Molina rapid and relationship our Florida, X% ahead. product numbers, as representing million cover expansion pleased be members approximately strong been further in the Molina, opportunity for of Continue to expand leaving the the with relationship have our at succession, addressable specialties multiple we Molina and to will footprint seven total product approximately
this to Suite. It’s Performance the Florida Molina understand allows establish that providers in market leadership market and the critical in that to continue to also fact Evolent in attractive confident importantly, Evolent important our most for and ability their are the with of for Evolent Florida because note and contract to to makes collaborate Molina providers to expansion scale track the Florida performance in and health both our with market. increasingly record market. plan Evolent’s the payers existing it the of with strong mass in
with our standard for therefore, and become to As easier work providers care payers providers services Evolent, use. of more a more of
pathways, time. agreement As network help Molina with share in the the facilitate and unique provider live We go Performance first growth members market XXX,XXX quarter given anticipate Suite approximately XXXX, over will familiar anticipate become opportunities new typical population our PMPMs. in Evolent effect and Medicaid and we any proficient at clinical additional of more this in increasingly can
a in with agreement and first-time million a health operating second logo members. The corporate new a with quarter is relationship plan level not-for-profit the over regional
Evolent agreement, the the quarter. will in third for This plan. of be going live helping environment part the health integrated vendors, more new will create specialty a agreement legacy several be replacing As
announce Beyond the operating two new sales. excited cross to we’re agreements, two significant
solutions. health an acquired strategic Shield either expands is the agreement acquisitions, and other. renews of product a is proof of services whereby agreement line Evolent contract a and an using or This all or Evolent some The products to one to in adopt NIA plan an specialty first the case technology recent product Blue plans simultaneously a the new Southeast. the of with Cross the elements an Blue into This business adds of of
believe the platform integrated we particular Blue be will Blue plan. product As this and broader a more Cross for was buying Shield case, often criterion key the
Finally, their the second Centene arrangement we’re surgery as Evolent’s management cross-sell members. announcing today for known whereby of formerly offering, will certain deploy IPG commercial
and announcement As seeing with are Cross our Shield evidence good working. we’re Blue Blue platform approaches product integrated the to cross-sell above,
above incremental $XX from million adjusted NIA into by built EBITDA solutions Centene estimate of with agreement is Centene’s which of fully synergized end over of the XXXX. of expansion was $XX This NIA the and from we anticipate of million EBITDA our
of value-based out Across all better see the solutions are four payers for for we innovative our agreements care integrate thesis patients large can multiple that looking specialty across specialties. announced playing today, that
challenging plans agreements. six our new groups country. and largest, Our into complex is strategy to These for new quality for to of announced and our risk-bearing physician annual a Evolent’s six medical of expanding compared and specialties the we resonating the most conversations total costs operating bring the eight agreements capabilities today basis to goal operating about leading how providing and deepening can in improve and partnership count
while opportunity. a new today, always logos target regional we remain Finally, plan like announced the
in noting as top are health into the out the plan right cross-sell plans time of the worth does over our indicated we in million Americans acquisition business large at Day and front focus, Our existing primary Investor the NIA opportunities $XX It’s of country footprint. that and insure have and of with direct Evolent XX XX five at us. cross-selling the of TAM XX four approximately plans, we’ve now those a reiterated of
our consolidate profile see on accelerating sales elevate absolutely with pipeline. value business domains. our vendors of recent because they helping MLRs nationally and seeing Regarding acquisitions the to of moving processes working clients to we’re accelerating contributing manage across are some to their or new us pipeline, our more an evidence Further, faster
addition, In with our RFP see lot more thesis solutions around recent our to from starting acquisitions. activity consistent we’re multispecialty a
for million. priority margin year-over-year quarter Adjusted Adjusted expanding second growing our quarter XX.X%, ago. the second year EBITDA adjusted quarter more for of X.X% to turn operating doubled one EBITDA. $XX.X Let’s from to than EBITDA totaled the
we’re year-over-year well mix maturation specialty adjusted we healthy as a as book. contributed of EBITDA, a from portion services benefiting acquisitions higher and performance technology the of While the of pull-through also of growth in
margin I we note, would and that perform Day Suite maturation focused ramp, time margin as is spent continuing to Performance on at the Investor expected.
Looking to and adjusted while forward, we’re of EBITDA revenues market $XXX share million run focused reaching XXXX, on thereafter. quickly exiting rate grow continuing
sales of quarterly achieve pipeline And to plan in of continued our confident from depth the we see momentum. $XXX we’re that can results and agreements our I confidence EBITDA. strong adjusted feel million mix you discussed, us the gives on As
populations the continue Obviously, manage it’s that Performance where have contracts. we and in Suite to utilization we costs, acuity important
elective for conflicting services, utilization We’re evidence Medicare. surgeries, costs and of of of increased demand higher care health reports pent-up particularly outpatient post-COVID in aware of and reports
our is For expected in screenings running utilization terms preventative trends normal the of part, over on heels to overall months XXXX returning of ago. XX as
guide with XXXX. on remains remainder You consistent the that our utilization based and results see expectations for can our the of
of strong let leading points to addition a the ahead. results our and XXXX the In to our QX data guide, indicator year-to-date across support me in results confidence quarters provide you QX couple the
mix-adjusted XXXX first of disease first combination per First, half authorizations the member basis. per our the a member XXXX in for the is own oncology of and of flat prevalence of on data generally half versus
Within numbers per increase overall member relatively on both a and cardiology, per the in some the are per prevalence below basis. expected remain also small growth member while prevalence disease authorizations, we’ve of member seen mix-adjusted XXXX and absolute and levels combination authorizations
favorable Medicaid benefit we at believe than cardiology a Overall, than Medicare experience more and trends both management across of conditions the be expectations. utilization from risk, across may diversified remain utilization other mix our direct we clinical populations. commercial, robust our hold that plans better We our we also likely oncology, and underwriting of and manage or because where
We utilization will course to continue monitor closely. of
optimal flow. our into capital to the relentless focus Our on third will walk allocation. do priority cash profitable our reiterate is I cash operating through growth dynamics want for you quarter. translating flow John
we capital third, allocation As and expect our on specialty strategic on structure. in three efficient M&A, of can care, two, as investing adjusted in to EBITDA to accelerate our a further capital is you one, can delever, see us discipline focus starting value-based and the capital results discipline and to priorities you which grows allocation the and and pay off maintaining leadership business
on to on Xx a we XX reiterated basis of leverage As of adjusted lowered below our our X.Xx X.Xx we Investor being end leverage net net month Day compared by the QX, ratio goal XXXX. and to March XX, trailing at
on markets. our stands for demand the close the macro profile integration front view where Let’s to Evolent at on and the midyear
health out rolled our and during innovation Evolent to our Investor a integration, logo roadmap, Since shared approach fact we the for our clients. product complex and Regarding One bringing information integrated platform integrated is we improve to new is people of Day. an officially market our to most new we’re and with amount then, costly The significant conditions. which what clients outcomes want, help
of The pace and continue while initial performance. feedback they’re pleased day-to-day extremely our is provide the clients integration with strong operational efforts, our positive from to we
Our focus clients with on that product innovation. to our impressed continue also tell us they’re
pilot an us the to system. making patients member Blue oncology earlier help program navigate promote example, that will to agreement As and patient enable decision navigation Blue their healthcare shared to we and will families the Cross the program plan. in better new navigation Shield the with recently journey a The signed provide engagement an
them members members care navigation by enhance them cancer options, and coordination, and of As very Care. a available clinical resources, will education nonclinical with possible part treatment and we to and goals well as early members members recent of capabilities, program, support program, their Care therapist our with cancer a or journey. to empower for order we meeting patients suspicion pilot with and preferences in this assisting their Advanced on we subset diagnosis, identify will proactive which to a plan as as an provide in of vital treatment Advanced diagnosis as their of where to make decisions is In through there early the acquired licensed them their care for outreach planning aligning
primary All seamless care this payer, occur care programs. oncologists the a and tightly a will in coordinated with to ensure other collaborative of and and providers coordination experience manner between
addressable on navigation product, to continue like other innovation drive our and Across innovation value-based product several an larger we towards of market strategic areas our with care addition to roadmap, intelligence. billion this eye entire focused artificial remain leadership in $XXX and rapid a market. plan larger long-term in In share we capturing specialty
With to over I’ll hand it John. that,
